Allergy immunotherapy gradually builds a person’s tolerance to specific allergens by exposing the patient to ever-increasing doses over a period of time – eventually reducing or eliminating symptoms. Read the rest of this entry »
Allergy and asthma medications are at the forefront of the U.S. Food and Drug Administration (FDA) agenda this year as the agency considers moving more drugs from prescription to over-the-counter (OTC) status.
Two medications recently considered were Nasacort®, the corticosteroid nasal spray approved for OTC use in late 2013, and Primatene HFA, an OTC asthma bronchodilator still under consideration at this time.
You don’t want to take a chance, so you call 911 or go directly to the local hospital emergency room (ER).
What then? Read the rest of this entry »
VIENNA, VA, FEB. 19, 2014 – An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.
On Feb. 25, FDA’s Nonprescription Drugs Advisory Committee and Read the rest of this entry »
In April 2013, the Food and Drug Administration (FDA) issued draft guidance that could allow new generic quick-relief albuterol inhalers onto pharmacy shelves without dose counters, leaving asthma patients playing a dangerous guessing game.
Read the rest of this entry »
McLEAN, VA, NOV. 13, 2013 – Allergy & Asthma Network Mothers of Asthmatics (AANMA) today commended President Obama for signing into law the School Access to Emergency Epinephrine Act, legislation that helps protect schoolchildren who experience anaphylaxis, a life-threatening allergic reaction.
On July 31, AANMA released results of our recent survey regarding patient use of intranasal corticosteroid sprays. Findings were shared during the Food and Drug Administration (FDA) Nonprescription Drug Advisory Committee meeting considering the switch of triamcinolone nasal spray from prescription to over-the-counter status.
After more than 50 years on the market, Primatene® Mist, the only nonprescription bronchodilator inhaler, will no longer be manufactured, sold or distributed in the United States as of Dec. 31, 2011. Why not? Because Primatene Mist, which is inhaled epinephrine, contains chlorofluorcarbon (CFC) propellants.
Kelsey never leaves home without it – her auto-injectable epinephrine, that is. In fact she always has two. You see, Kelsey is allergic to peanuts and while she does everything she can to avoid being exposed to them, she knows that accidents happen, Read the rest of this entry »
“With today’s news, we are able to reassure patients of the safety of these medications when used according to newly clarified label instructions Read the rest of this entry »